

Oncimmune Signs Three Further US Distribution Agreements

Total of seven distribution agreements signed covering the major markets of the US

Nottingham, UK – 25 May 2016: Oncimmune Holdings plc (AIM: ONC.L) (“Oncimmune” or the “Company” or the “Group”), a leading early cancer detection company developing and commercialising its proprietary *EarlyCDT*[®] platform technology, announces it has entered into three further distribution agreements in the US for its *EarlyCDT*[®]-Lung test.

The three agreements have been signed with national and regional distributors and will increase the total salesforce to more than 140 across the US. Amongst the roster of partners selling *EarlyCDT*[®]-Lung are Accu Reference Medical Lab and Stroke Detection Plus[®], each announced in March 2016. With these seven agreements in place, the Company now has distribution agreements covering the major US markets. Oncimmune is in discussions with several other distributors.

Geoffrey Hamilton-Fairley, CEO of Oncimmune said: *“More than 140,000 EarlyCDT[®]-Lung tests have been sold in the US since we began commercialisation in 2012. Our near term strategy in this market is to partner with more distributors and move towards total coverage across the US. Delivering on the strategy set out at IPO, we are pleased to announce three significant new partners today which now takes our total agreements in the US to seven - covering all the major US markets. We continue to explore further opportunities in the US and other regions and are in talks with several other distributors.”*

EarlyCDT[®]-Lung is a simple blood test to aid in the risk assessment and early detection of lung cancer. The test measures a panel of seven autoantibodies to detect the presence of lung cancer and has been developed so that individuals at high risk of developing lung cancer can benefit from an increased chance that lung cancer can be detected at earlier stages, when treatment can be most successful.

About Oncimmune

Oncimmune is a leading early cancer detection company developing and commercialising its proprietary *EarlyCDT*[®] platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company’s first product, *EarlyCDT*[®]-Lung, was launched in 2012, as a CLIA test in the USA and since then over 140,000 commercial tests have been sold. *EarlyCDT*[®]-Lung is available through physicians in the US and also privately in the UK and other regions. *EarlyCDT*[®]-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,000 high-risk smokers. *EarlyCDT*[®] tests for liver and ovarian cancer are in development.



Oncimmune, headquartered in Nottingham, United Kingdom with testing facilities in the US, joined AIM in May 2016 under the ticker ONC.L. For more information visit www.oncimmune.com

For further information:

Oncimmune Holdings plc
Geoffrey Hamilton-Fairley, Chief Executive Officer
contact@oncimmune.co.uk

Zeus Capital Limited (Nominated Adviser and Broker)
Phil Walker, Andrew Jones, Dominic Wilson
+44 (0) 203 829 5000

Media enquiries:
Consilium Strategic Communications
Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey Neville
oncimmune@consilium-comms.com
+44 (0) 20 3709 5708